Saxagliptin. Dipeptidyl peptidase IV inhibitor: Antidiabetic agent

Drugs of the Future

Volumn 33, Issue 7, 2008, Pages 577-586

  Cole, P ^a   Serradell, N ^a   Bolos J ^a   Castaner R ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ABT 279; ALOGLIPTIN BENZOATE; AMG 222; BI 1356; DIGOXIN; DILTIAZEM; DIPEPTIDYL PEPTIDASE IV INHIBITOR; FAMOTIDINE; GLIBENCLAMIDE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; KETOCONAZOLE; KRP 104; MELOGLIPTIN; METFORMIN; MP 513; ONGLYZA; PF 734200; PHX 1149; PIOGLITAZONE; PLACEBO; R 1579; SAXAGLIPTIN; SITAGLIPTIN; SK 0403; SULFONYLUREA DERIVATIVE; SYR 472; TA 6666; TAK 100; UNCLASSIFIED DRUG; UNINDEXED DRUG; VILDAGLIPTIN;

ADD ON THERAPY; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CHILL; CLINICAL TRIAL; CONSTIPATION; DIET THERAPY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; EXERCISE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN RESISTANCE; LOADING DRUG DOSE; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; QT INTERVAL; SIDE EFFECT; SINGLE DRUG DOSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; WEIGHT CHANGE;

EID: 56749165247     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2008.033.07.1229229     Document Type: Article

References (42)

1. Robl, J.A., Sulsky, R.B., Betebenner, D.A., Magnin, D.R., Hamann, L.G., Augeri, D.J. (Bristol-Myers Squibb Co.). Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method. EP 1261586, JP 2003531118, US 6395767, WO 0168603.
2. Vu, T.C., Hamann, L.G., Fox, R. et al. (Bristol-Myers Squibb Co.). Methods and compounds producing dipeptidyl peptidase IV inhibitors and intermediates thereof. JP 200651621, US 2005090539, WO 2004052850.
3. Politino, M., Cadin, M.M., Skonezny, P.M., Chen, J.G. (Bristol-Myers Squibb Co.). EP 1737970, JP 2007532137, WO 2005106011.
4. Sharma, P.N., Galvin, G.M., Boettger, S.D., Racha, S., Zhu, J., Melton, J., Mudryk, B. (Bristol-Myers Squibb Co.). Ammonolysis process for the preparation of intermediates for DPP IV inhibitors. US 2006035954, WO 2006020664.
5. Sharma, P.N. (Bristol-Myers Squibb Co.). Process for producing a dipeptidyl peptidase IV inhibitor. EP 1751102, US 2005267191, US 7214702, WO 2005115982.
6. Augeri, D.J., Robl, J.A., Betebenner, D.A. et al. Discovery and preclinical profile of saxagliptin (BMS-477118): A highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005, 48(15): 5025-37.
7. Sharma, P.N., Gublo, E.J., Galvin, G.M., Boettger, S.D., Racha, S. (Bristol-Myers Squibb Co.). Process for preparing a dipeptidyl peptidase IV inhibitor and intermediates employed therein. WO 2005094323.
8. Crepaldi, G., Carruba, M., Comaschi, M., Del Prato, S., Frajese, G., Paolisso, G. Dipeptidyl peptidase 4 (DPP-4) inhibitors and their role in type 2 diabetes management. J Endocrinol Invest 2007, 30(7): 610-4.
9. Narayan, K.M.V., Boyle, J.P., Thompson, T.J., Sorensen, S.W., Williamson, D.F. Lifetime risk for diabetes mellitus in the United States. JAMA 2003, 290(14): 1884-90.
10. Narayan, K.M., Boyle, J.P., Geiss, L.S., Saaddine, J.B., Thompson, T.J. impact of recent increase in incidence on future diabetes burden: U.S., 2005-2050. Diabetes Care 2006, 29(9): 2114-6.
11. Sloan, F.A., Bethel, M.A., Ruiz, D. Jr., Shea, A.M., Feinglos, M.N. The growing burden of diabetes mellitus in the US elderly population. Arch Intern Med 2008, 168(2): 192-9.
12. Alberti, G., Zimmet, P., Shaw, J. et al. Type 2 diabetes in the young: The evolving epidemic. The International Diabetes Federation Consensus Workshop. Diabetes Care 2004, 27(7): 1798-811.
13. Economic costs of diabetes in the U.S. in 2007. Diabetes Care 2008, 31(3): 596.
14. Gallwitz, B. Therapies for the treatment of type 2 diabetes meffitus based on incretin action. Minerva Endocrinol 2006, 31(2): 133-47.
15. Gallwitz, B. Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus. Treat Endocrinol 2005, 4(6): 361-70.
16. Arulmozhi, D.K., Protha, B. GLP-1 based therapy for type 2 diabetes. Eur J Pharm Sci 2006, 28(1-2): 96-108.
17. Langley, A.K., Suffoletta, T.J., Jennings, H.R. Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus. Pharmacotherapy 2007, 27(8): 1163-80.
18. Barnett, A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract 2006, 60(11): 1454-70.
19. Peters, J.-U. 11 Years of cyanopyrrolidines as DPP-IV inhibitors. Curr Top Med Chem 2007, 7(6): 579-95.
20. Kim, Y.B., Kopcho, L.M., Kirby, M.S. et al. Mechanism of Gly-Pro-pNA cleavage catalyzed by dipeptidyl peptidase-IV and its inhibition by saxagliptin (BMS-477118). Arch Biochem Biophys 2006, 445(1): 9-18.
21. List, J., Rosenstock, J., Sankoh, S., Chen, R. Saxagliptin improves glycaemic control as monotherapy in type 2 diabetes. Diabetologia [43rd Annu Meet Eur Assoc Study Diabetes (EASD) (Sept 17-21, Amsterdam) 2007] 2007, 50(Suppl. 1): Abst 0889.
22. Boulton, D.W., Geraldes, M. Safety, tolerability, pharmacokinetics and pharmacodynamics of once-daily oral doses of saxagliptin for 2 weeks in type 2 diabetic and healthy subjects. 67th Annu Meet Sci Sess Am Diabetes Assoc (ADA) (June 22-26, Chicago) 2007, Abst 606-P.
23. Defronzo, R.A., Hissa, M., Blauwet, M.B., Chen, R.S. Saxagliptin added to metformin improves glycemic control in patients with type 2 diabetes. 67th Annu Meet Sci Sess Am Diabetes Assoc (ADA) (June 22-26, Chicago) 2007, Abst 285-OR.
24. Study of BMS-477118 as monotherapy with titration in subjects with type 2 diabetes who are not controlled with diet and exercise (NCT00316082). ClinicalTrials.gov Web site, July 14, 2008.
25. Saxagliptin treatment in subjects with type 2 diabetes who are not controlled with diet and exercise (NCT00121641). ClinicalTrials.gov Web site, July 14, 2008.
26. A study of saxagliptin in subjects with type 2 diabetes who have inadequate blood sugar control with sulfonylureas (NCT00313313). ClinicalTrials.gov Web site, July 14, 2008.
27. A phase 3 study of BMS-477118 in combination with metformin in subjects with type 2 diabetes who are not controlled with diet and exercise (NCT00327015). ClinicalTrials.gov Web site, July 14, 2008.
28. A study assessing saxagliptin treatment in type 2 diabetic subjects who are not controlled with TZD therapy alone (NCT00295633). ClinicalTrials.gov Web site, July 14, 2008.
29. A study assessing saxagliptin treatment in subjects with type 2 diabetes who are not controlled with diet and exercise (NCT00374907). ClinicalTrials.gov Web site, July 14, 2008.
30. 52-Week add-on to metformin comparison of saxagliptin and sulphonylurea (NCT00575588). ClinicalTrials.gov Web site, July 14, 2008.
31. Treatment effect of saxagliptin compared with placebo in patients with type 2 diabetes and renal impairment (NCT00614939). ClinicalTrials.gov Web site, July 14, 2008.
32. Evaluate efficacy and safety of saxagliptin in combination with metformin in adult patients with type 2 diabetes (NCT00661362). ClinicalTrials.gov Web site, July 14, 2008.
33. Safety and efficacy study of subjects that are taking saxagliptin added onto metformin XR compared to subjects taking metformin XR alone (NCT00683657). ClinicalTrials.gov Web site, July 14, 2008.
34. Evaluate efficacy and safety of saxagliptin in adult patients with type 2 diabetes inadequate glycemic control (NCT00698932). ClinicalTrials.gov Web site, July 14, 2008.
35. Bristol-Myers Squibb and AstraZeneca submit NDA and MAA for Onglyza. DailyDrugNews.com, July 24, 2008.
36. Girgis, S., Patel, C.G., Li, L., Gooding, L., Frevert, U., Whigan, D., Boulton, D.W. Effect of diltiazem on the pharmacokinetics of saxagliptin in healthy subjects. J Clin Pharmacol [36th Annu Meet Am Coll Clin Pharmacol (ACCP) (Sept 9-11, San Francisco) 2007] 2007, 47(9): Abst 72.
37. Boulton, D.W., Brenner, E., Royzman, K., Li, L. Effect of ketoconazole on the pharmacokinetics of saxagliptin in healthy subjects. J Clin Pharmacol [36th Annu Meet Am Coll Clin Pharmacol (ACCP) (Sept 9-11, San Francisco) 2007] 2007, 47(9): Abst 89.
38. Patel, C., Li, L., Komoroski, B., Boulton, D. No meaningful pharmacokinetic drug-drug interaction between saxagliptin and pioglitazone in healthy subjects. Annu Meet Am Coll Clin Pharm (Oct 14-17, Denver) 2007, Abst 226.
39. Patel, C., Li, L., Komoroski, B., Boulton, D. No meaningful pharmacokinetic drug-drug interaction between saxagliptin and glyburide in healthy subjects. Annu Meet Am Coll Clin Pharm (Oct 14-17, Denver) 2007, Abst 212.
40. Patel, C., Li, L., Komoroski, B., Boulton, D. No meaningful pharmacokinetic drug-drug interaction between saxagliptin and metformin in healthy subjects. Annu Meet Am Coll Clin Pharm (Oct 14-17, Denver) 2007, Abst 213.
41. Boulton, D.W., Li, L., Patel, C.G., Komoroski, B.J., Whigan, D., Frevert, E.U., Kornhauser, D.M. No pharmacokinetic interaction between saxagliptin and digoxin in healthy subjects. Clin Pharmacol Ther [Annu Meet Am Soc Clin Pharmacol Ther (ASCPT) (April 2-5, Orlando) 2008] 2008, 83(Suppl. 3): Abst PIII-69.
42. Boulton, D.W., Adams, D., Li, L. et al. Magnesium and aluminum hydroxides plus simethicone, famotidine, or omeprazole do not meaningfully affect the pharmacokinetics of saxagliptin in healthy subjects. Clin Pharmacol Ther [Annu Meet Am Soc Clin Pharmacol Ther (ASCPT) (April 2-5, Orlando) 2008] 2008, 83(Suppl. 3): Abst PIII-68.